Stock 600867 TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Tonghua Dongbao Pharmaceutical Co., Ltd.

Equities

600867

CNE000000H87

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-06-26 EDT 		5-day change 1st Jan Change
8.44 CNY -2.31% Intraday chart for Tonghua Dongbao Pharmaceutical Co., Ltd. -3.32% -22.07%
06-21 Dongbao Pharmaceutical Doses First Patient in Diabetes Drug Trial MT
05-15 Tonghua Dongbao Pharmaceutical Launches Phase 1 Trial for Diabetes Injection in China MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Dongbao Pharmaceutical Doses First Patient in Diabetes Drug Trial
Tonghua Dongbao Pharmaceutical Launches Phase 1 Trial for Diabetes Injection in China
Dongbao Pharmaceutical's Deputy General Manager to Reduce Stake
Dongbao Pharmaceutical's Profit, Operating Income Slip in Q1 2024
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Dongbao Pharma's 2023 Profit Drops 26%
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Dongbao Pharma Unit's Gout Drug Clinical Study Achieves Primary Endpoint
Dongbao Pharmaceutical's Unit Gets Nod to Trial Diabetes Drug
Dongbao Pharmaceutical Unit Gets Nod to Trial Diabetes Drug
Tonghua Dongbao Pharma Unit Enrolls First Subject for Clinical Trial of Diabetes Drug
Tonghua Dongbao Pharma Registers Diabetes Drug
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Tonghua Dongbao Pharmaceutical's Insulin Injection Shows Positive Results in German Trial
Adocia : en nette hausse après des résultats positifs contre le diabète
Adocia Announces its Partner Tonghua Dongbao Releases Positive Results on the Three Clinical Studies Conducted on BioChaperone Combo THDB0207 Formulation Containing Insulin Glargine and Insulin Lispro from Tonghua Dongbao
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Announces an Exclusive Licensing Agreement with Tonghua Dongbao Pharmaceutical Co., Ltd. to Commercialize Three Insulin Biosimilars - Insulin Aspart, Insulin Lispro, and Insulin Glargine in the U.S
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Tonghua Dongbao Pharmaceutical Enrolls First Subject for Phase II Trial of Gout Drug; Shares Rose 4%
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600867 Stock
  4. News Tonghua Dongbao Pharmaceutical Co., Ltd.
  5. Other languages